Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This review summarizes key characteristics of men's health issues such as erectile dysfunction and prostate cancer, along with specific nursing considerations, and reports no new research results.

This article discusses the challenges in treating androgenic alopecia and highlights its potential links to coronary heart disease and metabolic syndrome but reports no new clinical findings.

This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.

This narrative review discusses issues in the treatment of epilepsy, focusing on antiepileptic drug compliance, side effects, and the challenges of drug selection; it reports no new clinical findings.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This abstract provides issue information for the Journal of the European Academy of Dermatology and Venereology without presenting any new research results.

This article reviews the lack of major breakthroughs and limited therapeutic options for extensive hair loss, emphasizing the need to address its psychological impact; it reports no new clinical results.

This study found that iron deficiency was common in both women with hair loss and control subjects, with no higher incidence in the hair loss group.

The document summarized various dermatology studies and case reports.

This review discusses cyclosporine A's mechanisms of action and side effects compared to tacrolimus in renal transplantation, but it reports no new experimental results; the authors highlight implications for cardiovascular risk management.

This special issue reviews recent progress in hair research discussed at the 2001 International Hair Workshop, reporting developments in androgen action, stem cell biology, and potential therapies for hair growth disorders without presenting new experimental results.

This article reviews the progress in hair biology research, including advancements in understanding androgen action, hair follicle stem cells, and autoimmune mechanisms in alopecia, and reports no new clinical results.

This study identified both known and additional potential adverse reactions to tralokinumab in real-world use for atopic dermatitis, highlighting the importance of monitoring adverse events, especially in the first month of treatment.

This document outlines the indications, dosing, side effects, and contraindications for Epilim in epilepsy treatment, with no new research findings presented.

This letter discusses the importance of microvascular disease in renal arterioles as a common cause of renal failure progressing to end-stage renal disease, a topic often overlooked in nephrology literature.

This study identified specific reflectance confocal microscopy features that help differentiate scarring from non-scarring alopecia, providing a non-invasive diagnostic tool.

This review discusses the potential role of vitamin D deficiency in cardiovascular and renal diseases and suggests that supplemental vitamin D could benefit cardiovascular outcomes, especially in African American and postmenopausal women; it reports no new clinical findings.

This study found that daily use of an emollient PLUS containing ADE-G1 significantly reduced xerosis severity and improved quality of life in cancer patients, regardless of their initial xerosis severity or cancer treatment.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

This collection of articles in AOGS includes findings on tetranectin as a possible prognostic marker for advanced ovarian cancer, and the effectiveness of tension-free vaginal tape for recurrent stress urinary incontinence.

This article introduces a special issue of "Lasers in Surgery and Medicine" focused on dermatology and plastic surgery, but it presents no new research findings.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This perspective suggests that browning agents may not directly enhance UCP1 expression in white adipose tissue but instead induce browning through increased heat loss, prompting thermogenesis to compensate.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

This pharmacovigilance study identified 19 drugs with high potential risk for causing male infertility, including hormonal agents, antineoplastic drugs, and antidepressants, emphasizing the need for fertility counseling and possible sperm cryopreservation in reproductive-age males before using such treatments.

This study found that high-fructose intake in rats led to significant kidney histological changes, such as podocyte damage and inflammatory responses, which persisted even after returning to a standard diet.

This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.

This article discusses various potential causes of hair loss in women undergoing renal replacement therapy and emphasizes the importance of thorough patient evaluation, but it reports no new research findings.